Evaluation of Topical Cysteamine Therapy in the CTNS(-/-) Knockout Mouse Using in Vivo Confocal Microscopy

Overview

Journal Mol Vis

Specialties Cell Biology
Molecular Biology
Ophthalmology

Date 2011 Nov 9

PMID 22065917

Citations 4

Authors

Jennifer L Simpson

Chyong Jy Nien

Kevin J Flynn

James V Jester

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to assess the ability of quantitative in vivo confocal microscopy (CM) to detect changes in cystine crystal volume in the cystinosisn (Ctns(-/-))mouse cornea following topical cysteamine therapy.

Methods: Fifteen Ctns(-/-) mice were sequentially followed using in vivo CM from 3 to 10 months of age. In a second experiment, five mice receiving topical cysteamine eyedrops (0.55%) for 4 weeks were compared to five untreated mice. The volume of corneal cystine crystals was determined by thresholding and counting high intensity pixels in the in vivo CM scans and dividing by the stromal volume to calculate a crystal volume index (CVI).

Results: Corneal crystals progressively increased in density with age, reaching a peak density at 6-8 months and showing a 70 fold increase in CVI. Eyes treated with cysteamine drops showed significantly less crystal accumulation compared to control eyes (p<0.001) with only a 15% increase in treated eyes (p=ns) compared to 173% increase (p<0.04) for untreated eyes.

Conclusions: Measurement of CVI shows that there is a progressive increase in cystine crystal volume up to 8 months of age and that cysteamine eyedrops significantly inhibits progression in the Ctns(-/-) mouse. These findings are similar to those seen clinically in patients with cystinosis, and suggest that measurement of CVI in the Ctns(-/-) mouse may be used as a model to develop novel therapeutic strategies for treating corneal cystinosis.

Citing Articles

Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses.

Pelusi L, Mandatori D, Mastropasqua L, Agnifili L, Allegretti M, Nubile M Pharmaceutics. 2023; 15(2).

PMID: 36839947 PMC: 9961328. DOI: 10.3390/pharmaceutics15020625.

Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Favret J, Weinstock N, Feltri M, Shin D Front Mol Biosci. 2020; 7:57.

PMID: 32351971 PMC: 7174556. DOI: 10.3389/fmolb.2020.00057.

Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.

Makuloluwa A, Shams F Clin Ophthalmol. 2018; 12:227-236.

PMID: 29416314 PMC: 5789046. DOI: 10.2147/OPTH.S133516.

Treatment of Inherited Eye Defects by Systemic Hematopoietic Stem Cell Transplantation.

Rocca C, Kreymerman A, Ur S, Frizzi K, Naphade S, Lau A Invest Ophthalmol Vis Sci. 2015; 56(12):7214-23.

PMID: 26540660 PMC: 4640476. DOI: 10.1167/iovs.15-17107.

References

Hsuan J, Harding J, Bron A . The penetration of topical cysteamine into the human eye. J Ocul Pharmacol Ther. 1996; 12(4):499-502. DOI: 10.1089/jop.1996.12.499. View

MacDonald I, Noel L, Mintsioulis G, Clarke W . The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J Pediatr Ophthalmol Strabismus. 1990; 27(5):272-4. DOI: 10.3928/0191-3913-19900901-14. View

Jones N, Postlethwaite R, Noble J . Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%. Br J Ophthalmol. 1991; 75(5):311-2. PMC: 1042364. DOI: 10.1136/bjo.75.5.311. View

Gahl W, Balog J, Kleta R . Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007; 147(4):242-50. DOI: 10.7326/0003-4819-147-4-200708210-00006. View

Kalatzis V, Cherqui S, Jean G, Cordier B, Cochat P, Broyer M . Characterization of a putative founder mutation that accounts for the high incidence of cystinosis in Brittany. J Am Soc Nephrol. 2001; 12(10):2170-2174. DOI: 10.1681/ASN.V12102170. View

Markello T, Bernardini I, Gahl W . Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med. 1993; 328(16):1157-62. DOI: 10.1056/NEJM199304223281604. View

Gahl W . Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr. 2003; 162 Suppl 1:S38-41. DOI: 10.1007/s00431-003-1349-x. View

Tsilou E, Rubin B, Reed G, Caruso R, Iwata F, Balog J . Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology. 2006; 113(6):1002-9. DOI: 10.1016/j.ophtha.2005.12.026. View

Forestier L, Jean G, Attard M, Cherqui S, Lewis C, Vant Hoff W . Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay. Am J Hum Genet. 1999; 65(2):353-9. PMC: 1377934. DOI: 10.1086/302509. View

10.

Fujikawa L, Kuwabara T, Jain S, Gahl W . Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med. 1987; 316(13):775-9. DOI: 10.1056/NEJM198703263161304. View

11.

Cherqui S, Kalatzis V, Forestier L, Poras I, Antignac C . Identification and characterisation of the murine homologue of the gene responsible for cystinosis, Ctns. BMC Genomics. 2000; 1:2. PMC: 29086. DOI: 10.1186/1471-2164-1-2. View

12.

Kalatzis V, Cordier B, Frishberg Y, Kemper M, Nuutinen E, Legrand E . Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis. Hum Mutat. 2002; 20(6):439-46. DOI: 10.1002/humu.10141. View

13.

Cantani A, Giardini O, DEufemia P . [The treatment of cystinosis with cysteamine]. Ann Pediatr (Paris). 1991; 38(6):440. View

14.

Tsilou E, Thompson D, Lindblad A, Reed G, Rubin B, Gahl W . A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol. 2002; 87(1):28-31. PMC: 1771471. DOI: 10.1136/bjo.87.1.28. View

15.

Simpson J, Nien C, Flynn K, Jester B, Cherqui S, Jester J . Quantitative in vivo and ex vivo confocal microscopy analysis of corneal cystine crystals in the Ctns knockout mouse. Mol Vis. 2011; 17:2212-20. PMC: 3164685. View

16.

Buchan B, Kay G, Heneghan A, Matthews K, Cairns D . Gel formulations for treatment of the ophthalmic complications in cystinosis. Int J Pharm. 2010; 392(1-2):192-7. DOI: 10.1016/j.ijpharm.2010.03.065. View

17.

Gahl W, Thoene J, Schneider J, ORegan S, Kuwabara T . NIH conference. Cystinosis: progress in a prototypic disease. Ann Intern Med. 1988; 109(7):557-69. DOI: 10.7326/0003-4819-109-7-557. View

18.

Cherqui S, Sevin C, Hamard G, Kalatzis V, Sich M, Pequignot M . Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol Cell Biol. 2002; 22(21):7622-32. PMC: 135682. DOI: 10.1128/MCB.22.21.7622-7632.2002. View

19.

Kalatzis V, Nevo N, Cherqui S, Gasnier B, Antignac C . Molecular pathogenesis of cystinosis: effect of CTNS mutations on the transport activity and subcellular localization of cystinosin. Hum Mol Genet. 2004; 13(13):1361-71. DOI: 10.1093/hmg/ddh152. View

20.

Tsilou E, Rubin B, Reed G, Iwata F, Gahl W, Kaiser-Kupfer M . Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea. 2002; 21(2):173-6. DOI: 10.1097/00003226-200203000-00009. View